Pfizer Inc.

NYSE:PFE   3:59:57 PM EDT
43.16
+0.30 (+0.70%)
5:18:50 PM EDT: $43.10 -0.06 (-0.14%)
Products, Regulatory

Pfizer Starts Global Phase 2/3 EPIC-PEP Study Of Novel Covid-19 Oral Antiviral Candidate For Post-Exposure Prophylaxis In Adults

Published: 09/27/2021 10:54 GMT
Pfizer Inc. (PFE) - Pfizer Starts Global Phase 2/3 Epic-pep Study of Novel Covid-19 Oral Antiviral Candidate for Post-exposure Prophylaxis in Adults.
Pfizer Inc - Results From Phase 1 Clinical Trial Demonstrated That Pf-07321332 Was Safe and Well Tolerated.
Pfizer Inc - New Study Will Evaluate Novel Protease Inhibitor for Prevention of Illness in Adults Living in Same Household As Someone With Covid-19.
Pfizer Inc - Primary Objective Will Assess Safety and Efficacy for Prevention of Confirmed Sars-cov-2 Infection and Its Symptoms Through Day 14.
Pfizer - Phase 2/3 Epic-pep Trial is Randomized, Double-blind, Placebo-controlled Study, to Enroll Up to 2,660 Healthy Adult Participants Aged 18 & Older.
Pfizer - Global Epic Program Consists of Multiple Ongoing Clinical Trials, Including 1 in Sars-cov-2 Infected Patients at High Risk of Severe Illness.